LEGN

Scotiabank Initiates Coverage of Legend Biotech Corporation - Depositary Receipt () (LEGN) with Sector Perform Recommendation

Fintel reports that on December 19, 2023, Scotiabank initiated coverage of Legend Biotech Corporation - Depositary Receipt () (NASDAQ:LEGN) with a Sector Perform recommendation.

Analyst Price Forecast Suggests 45.53% Upside

As of December 16, 2023, the average one-year price target for Legend Biotech Corporation - Depositary Receipt () is 89.88. The forecasts range from a low of 76.76 to a high of $105.00. The average price target represents an increase of 45.53% from its latest reported closing price of 61.76.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Legend Biotech Corporation - Depositary Receipt () is 206MM, a decrease of 11.67%. The projected annual non-GAAP EPS is -1.35.

What is the Fund Sentiment?

There are 446 funds or institutions reporting positions in Legend Biotech Corporation - Depositary Receipt (). This is an increase of 22 owner(s) or 5.19% in the last quarter. Average portfolio weight of all funds dedicated to LEGN is 0.46%, an increase of 6.67%. Total shares owned by institutions increased in the last three months by 2.09% to 99,640K shares. LEGN / Legend Biotech Corporation - Depositary Receipt (Common Stock) Put/Call Ratios The put/call ratio of LEGN is 0.24, indicating a bullish outlook.

What are Other Shareholders Doing?

LEGN / Legend Biotech Corporation - Depositary Receipt (Common Stock) Shares Held by Institutions

Price T Rowe Associates holds 9,693K shares representing 5.33% ownership of the company. In it's prior filing, the firm reported owning 9,031K shares, representing an increase of 6.83%. The firm increased its portfolio allocation in LEGN by 9.83% over the last quarter.

Hillhouse Capital Advisors holds 6,437K shares representing 3.54% ownership of the company. No change in the last quarter.

Ra Capital Management holds 6,265K shares representing 3.45% ownership of the company. No change in the last quarter.

SMCWX - SMALLCAP WORLD FUND INC holds 3,148K shares representing 1.73% ownership of the company. No change in the last quarter.

Capital World Investors holds 2,388K shares representing 1.31% ownership of the company. In it's prior filing, the firm reported owning 2,388K shares, representing a decrease of 0.01%. The firm increased its portfolio allocation in LEGN by 0.21% over the last quarter.

Legend Biotech Background Information
(This description is provided by the company.)

Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The team of over 800 employees across the United States, China and Europe, along with its differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture cutting edge cell therapies for patients in need.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.